Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen

AIDS

Volumn 14, Issue 16, 2000, Pages 2475-2478

  Moss, Ronald B ^a,c   Giermakowska, Wieslawa K ^a   Wallace, Mark R ^b   Savary, Jay R ^a   Jensen, Fred C ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c Immune Corporation   (United States)

Author keywords

CD4; Chemokines; HIV 1; Interferon ; Lymphocyte proliferative assay; T helper cell

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SERODIAGNOSIS; TREATMENT OUTCOME; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS LOAD;

AIDS VACCINES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEIN-1;

EID: 0033739604     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00008     Document Type: Article

References (15)

1. The Th1-Th2 hypothesis of HIV infection: New insights
2. HIV-1-specific functional immune measurements as markers of disease progression
3. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
4. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
5. Insights into HIV-specific immune function: Implications for therapy and prevention in the new millennium
6. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
7. Investigations of the use of beta-propiolactone in virus inactivation
8. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins
9. Sequence note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant
10. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa
11. In vitro p24 antigen-stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune)
12. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
13. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
14. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children
15. Enhancement of HIV-1 antigen-specific CD4+ T cell memory in subjects with chronic HIV-1 infection receiving HIV-1 immunogen